Intra-arterial thrombolytics during endovascular thrombectomy for acute ischaemic stroke in the MR CLEAN Registry

Autor: Sabine L Collette, Reinoud P H Bokkers, Aryan Mazuri, Geert J Lycklama à Nijeholt, Robert J van Oostenbrugge, Natalie E LeCouffe, Faysal Benali, Charles B L M Majoie, Jan Cees de Groot, Gert Jan R Luijckx, Maarten Uyttenboogaart
Přispěvatelé: Radiology and nuclear medicine, ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), MUMC+: MA Neurologie (3), MUMC+: Hersen en Zenuw Centrum (3), Klinische Neurowetenschappen, RS: Carim - B05 Cerebral small vessel disease, Beeldvorming, RS: Carim - B06 Imaging, Graduate School, ACS - Atherosclerosis & ischemic syndromes, ACS - Microcirculation, ANS - Neurovascular Disorders, Radiology and Nuclear Medicine
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Stroke and Vascular Neurology. BMJ Publishing Group
Stroke and vascular neurology, 8, 17-25. BMJ PUBLISHING GROUP
Stroke and Vascular Neurology, 8(1), 17-25. BMJ Publishing Group
Collette, S L, Bokkers, R P H, Mazuri, A, Lycklama À Nijeholt, G J, van Oostenbrugge, R J, Lecouffe, N E, Benali, F, Majoie, C B L M, de Groot, J C, Luijckx, G J R & Uyttenboogaart, M 2022, ' Intra-arterial thrombolytics during endovascular thrombectomy for acute ischaemic stroke in the MR CLEAN Registry ', Stroke and Vascular Neurology . https://doi.org/10.1136/svn-2022-001677
ISSN: 2059-8688
DOI: 10.1136/svn-2022-001677
Popis: IntroductionThe efficacy and safety of local intra-arterial (IA) thrombolytics during endovascular thrombectomy (EVT) for large-vessel occlusions is uncertain. We analysed how often IA thrombolytics were administered in the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) Registry, whether it was associated with improved functional outcome and assessed technical and safety outcomes compared with EVT without IA thrombolytics.MethodsIn this observational study, we included patients undergoing EVT for an acute ischaemic stroke in the anterior circulation from the MR CLEAN Registry (March 2014–November 2017). The primary endpoint was favourable functional outcome, defined as an modified Rankin Scale score ≤2 at 90 days. Secondary endpoints were reperfusion status, early neurological recovery and symptomatic intracranial haemorrhage (sICH). Subgroup analyses for IA thrombolytics as primary versus adjuvant revascularisation attempt were performed.ResultsOf the 2263 included patients, 95 (4.2%) received IA thrombolytics during EVT. The IA thrombolytics administered were urokinase (median dose, 250 000 IU (IQR, 1 93 750–2 50 000)) or alteplase (median dose, 20 mg (IQR, 12–20)). No association was found between IA thrombolytics and favourable functional outcome (adjusted OR (aOR), 1.16; 95% CI 0.71 to 1.90). Successful reperfusion was less often observed in those patients treated with IA thrombolytics (aOR, 0.57; 95% CI 0.36 to 0.90). The odds of sICH (aOR, 0.82; 95% CI 0.32 to 2.10) and early neurological recovery were comparable between patients treated with and without IA thrombolytics. For primary and adjuvant revascularisation attempts, IA thrombolytics were more often administered for proximal than for distal occlusions. Functional outcomes were comparable for patients receiving IA thrombolytics as a primary versus adjuvant revascularisation attempt.ConclusionLocal IA thrombolytics were rarely used in the MR CLEAN Registry. In the relatively small study sample, no statistical difference was observed between groups in the rate of favourable functional outcome or sICH. Patients whom required and underwent IA thrombolytics were patients less likely to achieve successful reperfusion, probably due to selection bias.
Databáze: OpenAIRE
Externí odkaz: